MedTrace Logo

Clinical Study of PSMA-targeted CAR-T Cells in the Treatment of Castration-resistant Prostate Cancer

NCT05354375 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2022-04-29

No results posted yet for this study

Summary

This is an experimental study to evaluate the safety and effectiveness of PSMA-targeted CAR-T cells in the treatment of castration-resistant prostate cancer.

Conditions

  • Immunotherapy

Interventions

BIOLOGICAL

CAR-T cell immunotherapy

This CAR-T cell immunotherapy with a novel specific Chimeric antigen receptor aiming at PSMA.

Sponsors & Collaborators

  • Xuzhou Medical University

    collaborator OTHER

  • The Affiliated Hospital of Xuzhou Medical University

    lead OTHER

Principal Investigators

  • Junnian Zheng, M.D/Ph.D · The Affiliated Hospital of Xuzhou Medical University

  • Hailong Li, M.D/Ph.D · The Affiliated Hospital of Xuzhou Medical University

  • Qing Zhang, Ph.D · Xuzhou Medical University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-12-01
Primary Completion
2025-11-30
Completion
2026-11-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05354375 on ClinicalTrials.gov